SCHEMBL1461741

SCHEMBL1461741

C=C(C)c1nc(N2CCCOCC2)cc(C)c1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
MAPT P10636 5/20 0.48
CYP1A2 P05177 3/20 0.48
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 2/20 0.48
KMT2A Q03164 5/20 0.43
MEN1 O00255 2/20 0.43
HPGD P15428 3/20 0.42
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 2/20 0.39
MAPK1 P28482 2/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971969 0.78 ALDH1A1 (0.59) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1441608 0.77 ALDH1A1 (0.46) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1441610 0.77 ALDH1A1 (0.46) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1462017 0.73 KMT2A (0.34) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1442112 0.71 MAPT (0.48) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1442108 0.71 MAPT (0.48) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL7886437 0.71 MAPT (0.53) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL5008170 0.69 ALDH1A1 (0.51) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL1461584 0.69 ALDH1A1 (0.34) ALDH1A1MAPTKMT2AMEN1HPGD
SCHEMBL6624247 0.68 MAPT (0.55) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232058-A1 SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2012-09-13 US disclosed
US-20120232058-A1 SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2012-09-13 US disclosed
WO-2011026891-A1 SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2011-03-10 WO disclosed
WO-2011026891-A1 SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232058-A1 SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR MEDICAL USE KCNA7, KCNN2, KCNN1 ALDH1A1 1672/4885MAPT 2794/4885CYP1A2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.